Back

Opening question.

28 August 2018 (11:00 - 11:00)
Organised by:
Congress Presentation Part of: First-line therapies in heart failure with reduced ejection fraction (HFrEF) - ACE inhibitors or sacubitril/valsartan? Pharmacotherapy ESC Premium Access ESC Congress 2018

7 More presentations in this session

Presentation thumbnail
Positioning of the topic - First-line therapies in heart failure with reduced ejection fraction (HFrEF)
Professor G. Filippatos (Athens, GR)
Slides Video
Presentation thumbnail
Sacubitril - Valsartan should be the starting treatment in HFrEF patients - PRO
Professor M. Packer (Dallas, US)
Slides Video
Presentation thumbnail
Sacubitril - Valsartan should be the starting treatment in HFrEF patients - CON
Professor A. Voors (Groningen, NL)
Slides Video
Presentation thumbnail
Sacubitril - Valsartan should be the starting treatment in HFrEF patients - Rebuttal PRO
Professor M. Packer (Dallas, US)
Video
Presentation thumbnail
Sacubitril - Valsartan should be the starting treatment in HFrEF patients - Rebuttal CON
Professor A. Voors (Groningen, NL)
Video

Access the full session

Session thumbnail
First-line therapies in heart failure with reduced ejection fraction (HFrEF) - ACE inhibitors or sacubitril/valsartan?

The Event

Event poster

ESC Congress 2018

28 August 2018 11:00 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Session
Navigating through heart failure device therapies
thumbnail
Congress Session
Acute heart failure therapies: from clinical trials to clinical practice

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources